The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist Rimonabant for nicotine dependence and weight loss with better psychiatric tolerability

International Journal of Neuropsychopharmacology

Volumn 19, Issue 12, 2016, Pages

  Gueye, Aliou B ^a   Pryslawsky, Yaroslaw ^a   Trigo, Jose M ^a   Poulia, Nafsika ^c   Delis, Foteini ^c   Antoniou, Katerina ^c   Loureiro, Michael ^d   Laviolette, Steve R ^d   Vemuri, Kiran ^e   Makriyannis, Alexandros ^e   Le Foll, Bernard ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF IOANNINA   (Greece)

^d WESTERN UNIVERSITY   (Canada)

^e NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anxiety; Cb1 antagonism; Depression; Dopamine; Nicotine reward

Indexed keywords

AM 4113; CANNABINOID 1 RECEPTOR ANTAGONIST; NICOTINE; RIMONABANT; UNCLASSIFIED DRUG; AM4113; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CNR1 PROTEIN, RAT; NICOTINE GUM; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG TOLERABILITY; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; WEIGHT REDUCTION; ADDICTION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; ANXIETY; ASSOCIATION; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SEEKING BEHAVIOR; INVERSE AGONISM; LONG EVANS RAT; MAZE TEST; METABOLISM; MOTIVATION; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION; SWIMMING; TIME FACTOR; WISTAR RAT;

ANIMALS; ANXIETY; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; CANNABINOID RECEPTOR ANTAGONISTS; CUES; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; DRUG-SEEKING BEHAVIOR; MALE; MAZE LEARNING; MESENCEPHALON; MOTIVATION; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RATS, LONG-EVANS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; SWIMMING; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; WEIGHT LOSS;

EID: 84995421250     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyw068     Document Type: Article

References (58)

1. 1 receptor antagonism. Neurobiol Dis 39:148-155.
2. Cahill K, Ussher MH (2011) Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev CD005353.
3. 1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293: R2185-2193.
4. Chauvet C, Nicolas C, Thiriet N, Lardeux MV, Duranti A, Solinas M (2014) Chronic stimulation of the tone of endogenous anandamide reduces cue-and stress-induced relapse in rats. Int J Neuropsychopharmacol 18.
5. Chiamulera C, Borgo C, Falchetto S, Valerio E, Tessari M (1996) Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (Berl) 127:102-107.
6. Cluny NL, Chambers AP, Vemuri VK, Wood JT, Eller LK, Freni C, Reimer RA, Makriyannis A, Sharkey KA (2011) The neutral cannabinoid CB (1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 97:537-543.
7. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81:387-395.
8. 1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30:145-155.
9. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB (1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
10. Cummings KM, Mahoney M (2006) Current and emerging treatment approaches for tobacco dependence. Current oncology reports 8:475-483.
11. de Bruin NM, Lange JH, Kruse CG, Herremans AH, Schoffelmeer AN, van Drimmelen M, De Vries TJ (2011) SLV330, a cannabinoid CB (1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res 217:408-415.
12. 1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420-426.
13. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154.
14. Doxey JC, Lane AC, Roach AG, Virdee NK (1984) Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol 325:136-144.
15. 1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183:394-403.
16. Erb S, Salmaso N, Rodaros D, Stewart J (2001) A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 158:360-365.
17. Forget B, Coen KM, Le Foll B (2009) Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB (1) receptor blockade. Psychopharmacology (Berl) 205:613-624.
18. 1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) 181:722-734.
19. Forget B, Pushparaj A, Le Foll B (2010) Granular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction. Biological Psychiatry 68:265-271.
20. Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B (2012) Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 17:47-61.
21. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Jama 296:47-55.
22. 1 cannabinoid receptors mediate nicotine-induced place preference. Prog Neuropsychopharmacol Biol Psychiatry 51:65-71.
23. 1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 193:298-305.
24. Janero DR, Makriyannis A (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14:43-65.
25. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63.
26. 1 receptor inverse agonists/antagonists in male Sprague-Dawley rats. FASEB J 24:581.7.
27. Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, Bergman J (2013) Cannabinoid discrimination and antagonism by CB (1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther 344:561-567.
28. Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaal J, Le Foll B (2010) The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacology 13:181-190.
29. Kodas E, Cohen C, Louis C, Griebel G (2007) Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology (Berl) 194:161-171.
30. Le AD, Funk D, Harding S, Juzytsch W, Fletcher PJ (2009) The role of noradrenaline and 5-hydroxytryptamine in yohimbineinduced increases in alcohol-seeking in rats. Psychopharmacology (Berl) 204:477-488.
31. 1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15:2139-2143.
32. 1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875-883.
33. Le Foll B, Pushparaj A, Pryslawsky Y, Forget B, Vemuri K, Makriyannis A, Trigo JM (2014) Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. Prog Neuropsychopharmacol Biol Psychiatry 52:86-93.
34. Lerman C, Lesage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6:746-762.
35. Liu X, Caggiula AR, Yee SK, Nobuta H, Sved AF, Pechnick RN, Poland RE (2007) Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Neuropsychopharmacology 32:710-718.
36. Lupica CR, Riegel AC (2005) Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48:1105-1116.
37. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232.
38. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Le AD (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol selfadministration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195:345-355.
39. 1 antagonist agent with anti-obesity activity and improved molecular profile. Behav Brain Res 234:192-204.
40. Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, Marcello S, Murineddu G, Lazzari P (2013) NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol Res 74:94-108.
41. Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI (2008) The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 326:483-492.
42. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA (2013) Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294-1301.
43. O'Brien LD, Wills KL, Segsworth B, Dashney B, Rock EM, Limebeer CL, Parker LA (2013) Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103:597-602.
44. Padwal RS, Majumdar SR (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77.
45. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, Group RI-NAS (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775.
46. Roberts DC, Bennett SA (1993) Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 111:215-218.
47. Sanofi Aventis (2008) Sanofi-Aventis to discountinue all clinical trials with Rimonabant. http://en. sanofi.com/Images/14245-20081105-rimonabant-en. pdf. Paris, Retrieved November 5, 2008.
48. Scatton B, Zivkovic B, Dedek J (1980) Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215:494-499.
49. Shoaib M (2006) Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence. Psychopharmacology (Berl) 188:252-257.
50. Shoaib M (2008) The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 54:438-444.
51. 1 receptor neutral antagonist AM4113 suppresses food intake and foodreinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946-955.
52. 1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology (Berl) 206:223-232.
53. 1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112-122.
54. 1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 91:303-306.
55. Tan H, Bishop SF, Lauzon NM, Sun N, Laviolette SR (2009) Chronic nicotine exposure switches the functional role of mesolimbic dopamine transmission in the processing of nicotine's rewarding and aversive effects. Neuropharmacology 56:741-751.
56. 1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 29:1761-1771.
57. Winter JC, Rabin RA (1992) Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 263:682-689.
58. World Health Organization (WHO, July, 2013) http://www.who. int/mediacentre/factsheets/fs339/en/(www.who.int) (www.who.int (www.who.int)). Tobacco Fact sheet, Retrieved March 12, 2014.